Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine, Inc. (Nasdaq: PRME) reported financial results for Q1 2024, highlighting FDA clearance of its first-ever IND application for PM359 for CGD treatment. They also presented new preclinical data demonstrating Prime Editing technology's potential and appointed Tony Coles, M.D., as a senior advisor. The company is focused on advancing its pipeline programs and strengthening its Prime Editing platform.
Prime Medicine, Inc. presents preclinical data showing PM359's ability to correct CGD mutation, with FDA clearance for Phase 1/2 trial. CGD is a rare disease causing severe infections. PM359 demonstrated high correction rates, restored neutrophil function, and clinical-scale production of edited cells.
Prime Medicine, Inc. (Nasdaq: PRME) will participate in the 27th Annual Milken Institute Global Conference with its CEO, Dr. Keith Gottesdiener, discussing cutting-edge technologies and scientific breakthroughs. The panel aims to offer insights into the future and will be livestreamed on May 8, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.